Pet isotope pylarify (F-18 psma)
Ended Awarded Last action
- Contract number
- 36C24424F0066
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 4
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $941,876
Award facts
- Contract value 100% obligated
- $941,875.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lebanon, PA 17042, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$39,696 | |
| Supplemental Agreement for work within scope | $54,131 | |
| Supplemental Agreement for work within scope | $162,392 | |
| Funding Only Action | -$46,913 | |
| Supplemental Agreement for work within scope | $126,305 | |
| Exercise an Option | $342,828 | |
| Original award | $342,828 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a delivery order valued at $941,875.92 by Veterans Integrated Service Network 4 on January 1, 2024, for the supply of PET Isotope PYLARIFY (F-18 PSMA), a radioactive diagnostic imaging agent used in positron emission tomography scans for prostate cancer detection and localization. This firm fixed-price delivery order, with an ultimate completion date of December 31, 2025, was issued without a set-aside designation and represents performance at the contractor's facility in Lebanon, Pennsylvania. The award is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), the master contract vehicle through which the Veterans Health Administration and Defense Health Agency procure radiopharmaceutical products from Lantheus and its subsidiaries.
Progenics maintains an extensive federal contracting portfolio with over 150 individual awards across multiple Veterans Integrated Service Networks, the Defense Health Agency, and the National Institutes of Health, establishing the company as a primary supplier of PYLARIFY radiopharmaceuticals to the federal healthcare system. The company holds substantial indefinite delivery vehicles including a $290 million Federal Supply Schedule contract awarded by Veterans Integrated Service Network 12 extending through March 31, 2030, multiple blanket purchase agreements with individual VISNs valued between $793,918 and $9.07 million, and Defense Health Agency blanket purchase agreements valued up to $1 million. These master contract frameworks enable efficient procurement of critical diagnostic imaging supplies supporting prostate cancer diagnostic initiatives and medical imaging programs across VA medical centers and military treatment facilities nationwide.
Quick answers
Who was awarded contract 36C24424F0066?
36C24424F0066 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 4 (Veterans Health Administration) on January 1, 2024.
How much is contract 36C24424F0066 worth?
The government has obligated $941,876 on 36C24424F0066.
Is contract 36C24424F0066 an order under another contract?
Yes. 36C24424F0066 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24424F0066 competed?
The extent of competition for 36C24424F0066 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award